Entera Bio Ltd. (ENTX)
$
1.85
+0.03 (1.62%)
Key metrics
Financial statements
Free cash flow per share
-0.1463
Market cap
83.9 Million
Price to sales ratio
376.0507
Debt to equity
0.0114
Current ratio
13.0733
Income quality
0.6277
Average inventory
0
ROE
-0.4672
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Entera Bio Ltd. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing orally delivered large molecule therapeutics to address unmet medical needs. The company incurred an income tax expense of $14,000.00 indicating its tax obligations. The cost of revenue for the company is $172,000.00 showcasing its production and operational expenses. The gross profit ratio is 0.05 reflecting the efficiency of the company's production and sales operations. In terms of investment income, the company earned an interest income of $0.00 which highlights its financial investments. The diluted EPS is -$0.25 accounting for potential share dilution. Entera's lead product candidates include EB612, currently in Phase II clinical trials for hypoparathyroidism, and EB613, which has completed Phase II clinical trials for osteoporosis and is also in Phase I clinical trials for the treatment of non-union fractures. Additionally, the company has established a research collaboration and license agreement with Amgen Inc. to further the development of clinical candidates in the field of inflammatory diseases and other serious illnesses. Founded in 2009, Entera Bio Ltd. is based in Jerusalem, Israel. The stock is affordable at $1.82 making it suitable for budget-conscious investors. It belongs to the Healthcare sector, driving innovation and growth, while being a key player in the Biotechnology industry, contributing significantly to the overall market landscape. With a market capitalization of $83,859,309.00 the company is classified as a small-cap player. Moreover, the stock has a low average trading volume of 45,311.00 indicating lower market activity. This profile reveals a firm engaged in critical therapeutic advancements, while also maintaining a financial structure that supports both operations and potential future growth, appealing to stakeholders seeking investment opportunities in promising health solutions.
Is Entera Bio Ltd. (ENTX) a good investment?
Investing in Entera Bio Ltd. (ENTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Entera Bio Ltd. (ENTX)'s stock forecast?
Analysts predict Entera Bio Ltd. stock to fluctuate between $1.41 (low) and $2.79 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Entera Bio Ltd.'s market capitalization?
As of 2025-05-30, Entera Bio Ltd.'s market cap is $83,859,309, based on 45,452,200 outstanding shares.
How does Entera Bio Ltd. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Entera Bio Ltd. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Entera Bio Ltd. (ENTX) stock?
To buy Entera Bio Ltd. (ENTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Entera Bio Ltd.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Entera Bio Ltd. perform in the last earnings report?
Revenue: $181,000 | EPS: -$0.25 | Growth: -19.35%.
Where can I find Entera Bio Ltd.'s investor relations reports?
Visit https://www.enterabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Entera Bio Ltd.?
You can explore historical data from here
What is the all-time high and low for Entera Bio Ltd. stock?
All-time high: $10.16 (2021-03-12) | All-time low: $0.47 (2022-11-11).
What are the key trends affecting Entera Bio Ltd. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
22 days ago
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.
globenewswire.com
2 months ago
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.
globenewswire.com
2 months ago
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year.
globenewswire.com
3 months ago
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.
globenewswire.com
4 months ago
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11 – 12, 2025 in a virtual format.
zacks.com
7 months ago
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.
globenewswire.com
7 months ago
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.
zacks.com
8 months ago
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
globenewswire.com
8 months ago
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss.
zacks.com
8 months ago
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.
See all news
